T1	Intervention 32 57	afatinib versus cetuximab
T2	Intervention 555 593	open-label, randomized, phase II trial
T3	Intervention 641 722	randomized (1 : 1) to either afatinib (50 mg/day) or cetuximab (250 mg/m(2)/week)
T4	Intervention 796 831	with optional crossover (stage II).
T5	Intervention 2023 2081	Sequential EGFR/ErbB treatment with afatinib and cetuximab
